People: GlaxoSmithKline PLC (GSK.L)

GSK.L on London Stock Exchange

1,463.00GBp
27 Aug 2014
Price Change (% chg)

15.50p (+1.07%)
Prev Close
1,447.50p
Open
1,448.50p
Day's High
1,464.50p
Day's Low
1,448.00p
Volume
9,047,575
Avg. Vol
8,063,224
52-wk High
1,709.00p
52-wk Low
1,365.00p

Search Stocks

Vallance, Patrick 

Brief Biography

Mr. Patrick Vallance is President - Pharmaceuticals R&D of Glaxosmithkline Plc., since January 2012. Prior to his appointment he was Senior Vice President, Medicines Discovery and Development. Patrick joined the company in 2006 as Head of Drug Discovery. He focused the organisation on science that has the best chance of leading to new medicines, and created small, multidisciplinary teams called Discovery Performance Units. He is transforming the way in which we approach late stage clinical trial design and execution. Prior to joining GSK Patrick was a clinical academic at University College London. Patrick is a member of the Board of the Agency for Science, Technology & Research (A*STAR) and is a director of Genome Research Limited.

Basic Compensation

Total Annual Compensation, Long-Term Incentive Plans, All Other, Fiscal Year Total,
-- -- -- --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Christopher Gent

734,000

Andrew Witty

7,207,000

Simon Dingemans

3,292,000

Moncef Slaoui

8,414,000

Deirdre Connelly

--

Roger Connor

--
As Of 30 Dec 2013
Search Stocks